ENTA - Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc Logo

ENTA - Enanta Pharmaceuticals Inc

https://www.enanta.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.

52W High
$13.37
52W Low
$4.09
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.85
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-0.29
EV/Revenue (<3 favorable)
0.67
P/S (TTM) (<3 favorable)
2.92
P/B (<3 favorable)
2.39
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
6.55%
Institutions (25–75% balanced)
86.58%
Shares Outstanding
21,377,900
Float
14,331,300
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
64,806,000
Gross Profit (TTM)
64,806,000
EPS (TTM)
-4.32
Profit Margin (>10% good)
-1.42%
Operating Margin (TTM) (higher better)
-1.03%
ROE (TTM) (>15% strong)
-0.81%
EPS YoY (Quarterly) (>10% good)
-0.66
Revenue YoY (Quarterly) (>8% good)
0.02
Momentum
Bearish momentum
Value
0.2560
Previous
0.3240
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025